1-20 of 122
Sort by
News

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL

Free
Khylia Marshall
Published: 2025
Abstract
June 2025
View News titled, MRD-Guided Treatment Approach Leads to Deep Remissions in CLL
News

Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

Free
Anna Azvolinsky, PhD
Published: 2025
Abstract
July 2025
View News titled, Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib
News

Results Detail Comparison of Patients With R/R CLL/SLL in Liso-Cel TRANSCEND CLL 004 Trial With Real-World Cohort

Free
Anna Azvolinsky, PhD
Published: 2025
Abstract
July 2025
View News titled, Results Detail Comparison of Patients With R/R CLL/SLL in Liso-Cel TRANSCEND CLL 004 Trial With Real-World Cohort
News

Patients With R/R CLL/SLL Achieve Tumor Response With DZD8586

Free
Thomas R. Collins
Published: 2025
Abstract
July 2025
View News titled, Patients With R/R CLL/SLL Achieve Tumor Response With DZD8586
News

Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL

Free
Thomas R. Collins
Published: 2025
Abstract
July 2025
View News titled, Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL
News

Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
May 2025
View News titled, Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL
News

CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds

Free
Thomas R. Collins
Published: 2024
Abstract
January 2025
View News titled, CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds
News

Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL

Free
Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL
News

MRD-Guided Therapy Improves Quality of Life for Patients With CLL

Free
Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, MRD-Guided Therapy Improves Quality of Life for Patients With CLL
News

Pirtobrutinib Combinations Effective in Small Study

Free
Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, Pirtobrutinib Combinations Effective in Small Study
News

Analysis Finds CLL-IPI Performs Poorly When Predicting Survival for Patients Treated With Targeted Therapies

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Analysis Finds CLL-IPI Performs Poorly When Predicting Survival for Patients Treated With Targeted Therapies
News

CAR-T Therapy Effective for Richter Transformation

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, CAR-T Therapy Effective for Richter Transformation
News

Venetoclax Plus Obinutuzumab a Viable Option for Newly Diagnosed CLL

Free
Anna Azvolinsky, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Venetoclax Plus Obinutuzumab a Viable Option for Newly Diagnosed CLL
News

MRD Helpful in Predicting Progression-Free Survival in CLL

Free
Thomas R. Collins
Published: 2024
Abstract
December Supplement 2024
View News titled, MRD Helpful in Predicting Progression-Free Survival in CLL
News

Long-Lasting, Deep Remissions Seen in R/R CLL with Triple Combination Therapy

Free
Anna Azvolinsky, PhD
Published: 2024
Abstract
December Supplement 2024
View News titled, Long-Lasting, Deep Remissions Seen in R/R CLL with Triple Combination Therapy
News

CLL Precursor Condition Linked with Melanoma Risk

Free
Leah Lawrence
Published: 2024
Abstract
Mid-November 2024
View News titled, CLL Precursor Condition Linked with Melanoma Risk
News

Forging a New Standard of Care for Hairy Cell Leukemia

Free
Anna Azvolinsky, PhD
Published: 2024
Abstract
October 2024
View News titled, Forging a New Standard of Care for Hairy Cell Leukemia
News

Fixed-Duration Regimen Safe, Effective for CLL

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
October 2024
View News titled, Fixed-Duration Regimen Safe, Effective for CLL
News

Phase II CAPTIVATE Study: The 5.5-Year Update

Free
Lara C. Pullen, PhD
Published: 2024
Abstract
Mid-July 2024
View News titled, Phase II CAPTIVATE Study: The 5.5-Year Update
News

Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi

Free
Ruth Jessen Hickman, MD
Published: 2024
Abstract
Mid-July 2024
View News titled, Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi